These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

359 related articles for article (PubMed ID: 9834048)

  • 41. Pharmacodynamic profile of Zaleplon, a new non-benzodiazepine hypnotic agent.
    Patat A; Paty I; Hindmarch I
    Hum Psychopharmacol; 2001 Jul; 16(5):369-392. PubMed ID: 12404558
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Post-bedtime dosing with indiplon in adults and the elderly: results from two placebo-controlled, active comparator crossover studies in healthy volunteers.
    Farber RH; Burke PJ
    Curr Med Res Opin; 2008 Mar; 24(3):837-46. PubMed ID: 18257978
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Preference of insomniac patients between a single dose of zolpidem 10 mg versus zaleplon 10 mg.
    Allain H; Bentué-Ferrer D; Breton SL; Polard E; Gandon JM
    Hum Psychopharmacol; 2003 Jul; 18(5):369-74. PubMed ID: 12858323
    [TBL] [Abstract][Full Text] [Related]  

  • 44. EEG profile of intravenous zolpidem in healthy volunteers.
    Patat A; Trocherie S; Thebault JJ; Rosenzweig P; Dubruc C; Bianchetti G; Court LA; Morselli PL
    Psychopharmacology (Berl); 1994 Feb; 114(1):138-46. PubMed ID: 7846196
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Comparative pharmacodynamics of Ro 41-3696, a new hypnotic, and zolpidem after night-time administration to healthy subjects.
    Dingemanse J; Bury M; Bock J; Joubert P
    Psychopharmacology (Berl); 1995 Nov; 122(2):169-74. PubMed ID: 8848532
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The clinical and forensic toxicology of Z-drugs.
    Gunja N
    J Med Toxicol; 2013 Jun; 9(2):155-62. PubMed ID: 23404347
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Zolpidem and triazolam do not affect the nocturnal sleep-induced memory improvement.
    Meléndez J; Galli I; Boric K; Ortega A; Zuñiga L; Henríquez-Roldán CF; Cárdenas AM
    Psychopharmacology (Berl); 2005 Aug; 181(1):21-6. PubMed ID: 15830236
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Pharma-clinics. Drug of the month. Zaleplon (Sonata)].
    Ansseau M
    Rev Med Liege; 1999 Aug; 54(8):705-6. PubMed ID: 10548901
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Ketoconazole inhibition of triazolam and alprazolam clearance: differential kinetic and dynamic consequences.
    Greenblatt DJ; Wright CE; von Moltke LL; Harmatz JS; Ehrenberg BL; Harrel LM; Corbett K; Counihan M; Tobias S; Shader RI
    Clin Pharmacol Ther; 1998 Sep; 64(3):237-47. PubMed ID: 9757147
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Long-term use of sedative hypnotics in older patients with insomnia.
    Ancoli-Israel S; Richardson GS; Mangano RM; Jenkins L; Hall P; Jones WS
    Sleep Med; 2005 Mar; 6(2):107-13. PubMed ID: 15716214
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Effects of alcohol, zolpidem, and some other sedatives and hypnotics on human performance and memory.
    Mattila MJ; Vanakoski J; Kalska H; Seppälä T
    Pharmacol Biochem Behav; 1998 Apr; 59(4):917-23. PubMed ID: 9586849
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Zaleplon shortens subjective sleep latency and improves subjective sleep quality in elderly patients with insomnia. The Zaleplon Clinical Investigator Study Group.
    Hedner J; Yaeche R; Emilien G; Farr I; Salinas E
    Int J Geriatr Psychiatry; 2000 Aug; 15(8):704-12. PubMed ID: 10960882
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The pharmacology and mechanisms of action of new generation, non-benzodiazepine hypnotic agents.
    Sanger DJ
    CNS Drugs; 2004; 18 Suppl 1():9-15; discussion 41, 43-5. PubMed ID: 15291009
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Zaleplon and triazolam physical dependence assessed across increasing doses under a once-daily dosing regimen in baboons.
    Ator NA; Weerts EM; Kaminski BJ; Kautz MA; Griffiths RR
    Drug Alcohol Depend; 2000 Dec; 61(1):69-84. PubMed ID: 11064185
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Determination of zaleplon and zolpidem by liquid chromatography-turbo-ionspray mass spectrometry: application to forensic cases.
    Giroud C; Augsburger M; Menetrey A; Mangin P
    J Chromatogr B Analyt Technol Biomed Life Sci; 2003 Jun; 789(1):131-8. PubMed ID: 12726851
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Assessment of the abuse liability of a dual orexin receptor antagonist: a crossover study of almorexant and zolpidem in recreational drug users.
    Cruz HG; Hoever P; Chakraborty B; Schoedel K; Sellers EM; Dingemanse J
    CNS Drugs; 2014 Apr; 28(4):361-72. PubMed ID: 24627301
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Comparative tolerability, pharmacodynamics, and pharmacokinetics of a metabolite of a quinolizinone hypnotic and zolpidem in healthy subjects.
    Dingemanse J; Bury M; Hussain Y; van Giersbergen P
    Drug Metab Dispos; 2000 Dec; 28(12):1411-6. PubMed ID: 11095577
    [TBL] [Abstract][Full Text] [Related]  

  • 58. In the Zzz zone: the effects of Z-drugs on human performance and driving.
    Gunja N
    J Med Toxicol; 2013 Jun; 9(2):163-71. PubMed ID: 23456542
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Zaleplon and driving impairment.
    Stillwell ME
    J Forensic Sci; 2003 May; 48(3):677-9. PubMed ID: 12762547
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Triazolam and zolpidem: effects on human memory and attentional processes.
    Mintzer MZ; Griffiths RR
    Psychopharmacology (Berl); 1999 May; 144(1):8-19. PubMed ID: 10379619
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.